Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
A Non-Interventional Extension Study to Investigate Vulvovaginal Candidiasis Recurrence and Candida Colonization Following a Phase 2 Randomized, Active-Controlled Study of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Precision Trials AZ
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- The Women's Clinical, P.A.
-
-
California
-
San Diego, California, United States, 92111
- Women's Health Care Research Corp
-
-
Florida
-
Clearwater, Florida, United States, 33756
- Olympian Clinical Research
-
Clearwater, Florida, United States, 33759
- Women's Medical Research
-
Lake Worth, Florida, United States, 33461
- Altus Research Inc
-
Miami, Florida, United States, 33186
- New Age Medical Research Corporation
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Augusta University
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Clinical Trials Management LLC
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Wayne State University
-
Saginaw, Michigan, United States, 48604
- Saginaw Valley Medical Research Group LLC
-
-
New Jersey
-
Delran, New Jersey, United States, 08075
- Alliance Women's Research Group LLC
-
Lawrenceville, New Jersey, United States, 08648
- Lawrence OB GYN Clinical Research LLC
-
-
New York
-
Port Jefferson, New York, United States, 11777
- Soffolk OB/GYN
-
-
North Carolina
-
New Bern, North Carolina, United States, 28562
- Eastern Carolina Women's Center
-
Winston-Salem, North Carolina, United States, 27103
- Hawthorne Medical Research Inc
-
Winston-Salem, North Carolina, United States, 27103
- Unified Women's Clinical Research - Hickory
-
-
Ohio
-
Columbus, Ohio, United States, 43123
- Women's Health Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19102
- Drexel University
-
-
Texas
-
Houston, Texas, United States, 77054
- TMC Life Research Inc.
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas Inc
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Tidwewater Physicians for Women
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Women's Health, Research, Gynecology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Enrollment in and completed the primary study through the Day 28 visit.
- Received at least one dose of study drug in the primary study
- Able to give written informed consent prior to completion of the primary study
Exclusion Criteria:
- Received systemic or topical vaginal non-study antifungal therapy at any time during the primary study
- Diagnosed with bacterial vaginosis, trichomonas, gonorrhea, chlamydia, or active herpes at any point during the primary study
- The Principal Investigator considers that the subject should not participate in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to recurrence of clinical signs/symptoms of VVC
Time Frame: Up to Day 90 +/- 14 days
|
Time to recurrence of clinical signs/symptoms of VVC
|
Up to Day 90 +/- 14 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of candida colonization
Time Frame: Up to Day 90 +/- 14 days
|
Rate of candida colonization
|
Up to Day 90 +/- 14 days
|
|
Rate of recurrence of clinical signs/symptoms of VVC
Time Frame: Up to Day 90 +/- 14 days
|
Rate of recurrence of clinical signs/symptoms of VVC
|
Up to Day 90 +/- 14 days
|
|
Time to recurrence of culture confirmed VVC
Time Frame: Up to Day 90 +/- 14 days
|
Time to recurrence of culture confirmed VVC
|
Up to Day 90 +/- 14 days
|
|
Rates of recurrence of culture confirmed VVC
Time Frame: Up to Day 90 +/- 14 days
|
Rates of recurrence of culture confirmed VVC
|
Up to Day 90 +/- 14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Alena Jandourek, MD, Cidara Therapeutics
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CD101.TP.2.02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.